Topical wet AMD therapy passes first test with success

A Phase I clinical study of Athenagen's topical eye drop therapy for wet age-related macular degeneration (AMD), ATG3, has found it to be safe and well tolerated.

A Phase I clinical study of Athenagen's topical eye drop therapy for wet age-related macular degeneration (AMD), ATG3, has found it to be safe and well tolerated.

The randomized, double-masked, placebo-controlled study enrolled 80 healthy subjects to receive single and multiple dose ascending regimens for up to two weeks. No medication-related systemic side effects were noted and the therapy demonstrated good ocular tolerability.

A Phase II trial is expected to be initiated soon and will be a placebo-controlled, double-masked, randomized dose-ranging study, evaluating both safety and efficacy.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Clinical trials in wet AMD: Impact of central subfield thickness, volatility on visual acuity
Post hoc analysis of Copernicus, Galileo trials find time since diagnosis affects BCVA outcomes in CRVO
Related Content
© 2023 MJH Life Sciences

All rights reserved.